Heart surgery A battery-operated left ventricular-assist system–LVAS implanted between the heart and aorta which pumps blood, a bridge for Pts awaiting heart transplant, allowing Pt outpatient mobility. See Heart transplant, Jarvik 7.
Mentioned in ?
References in periodicals archive ?
The deal will add the HeartMate IIA VAD, the most extensively used and widely studied left ventricular assist device (VAD), as well as the next generation HeartMate 3 , HeartMate PHP devices and other complementary products to the market-leading heart failure portfolio of St.
The company's products include the HeartMate II and HeartMate 3(TM) LVAS (Left Ventricular Assist Systems) and Thoratec VAD (Ventricular Assist Device) with more than 20,000 devices implanted in patients suffering from heart failure.
reported the first-ever HeartMate 3 implant performed via mini-thoracotomy (surgical opening of the chest).
Thortec Corporation, Pleasanton, CA, announced in late June that its CE Mark Clinical Trial for HeartMate III commenced with its first patient implanted with its new device.
The hospital has successfully performed India's first HeartMate II LVAD (Left Ventricular Assist Device) implant on a 58-year-old gentleman suffering from chronic heart failure.
The approval of the HeartMate II, the continuous-flow left ventricular assist device, has been expanded to include its use as destination therapy for people with severe heart failure who are not acceptable candidates for heart transplantation.
Baptist Health said last week that the HeartMate II left ventricular assist system had received FDA approval for Destination Therapy, which is a long-term treatment option for patients suffering from advanced stage heart failure who are not eligible for heart transplantation.
a world leader in products to treat cardiovascular disease, said today that it has completed the submission of its PMA (Pre-Market Approval) seeking bridge-to-transplantation (BTT) approval for its HeartMate II LVAS (left ventricular assist system) by filing the clinical summary and draft final labeling module.
patient to be implanted with Thoratec's HeartMate II.
The approval of the pump device, the HeartMate II, follows several years of clinical trials and is seen as a major milestone for patients in the United States.
6, 2015 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, highlighted recent clinical presentations from the European Association for Cardio-Thoracic Surgery (EACTS) annual meeting in Amsterdam, including three presentations that build upon the positive initial data from the HeartMate 3 CE Mark trial that was recently presented at the Heart Failure Society of America conference.